Clinical trial
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are…
NCT00081055 · Mesoblast International Sàrl, Industry · Withdrawn
Key facts
| NCT number | NCT00081055 |
|---|---|
| Title | OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies |
| Official title | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OTI-010 in Subjects Who Receive HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies |
| Lead sponsor | Mesoblast International Sàrl, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate, peripheral blood stem cell transplantation, radiation therapy |
| Enrollment | 0 |
| First posted | Apr 8, 2004 |
| Last update posted | Dec 4, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: